Ref ID: 18570
Author:
M. Di Ianni (1), F. Falzetti (1), A. Carotti (1), A. Terenzi (1),
E. Bonifacio (1), K. Perruccio (1), B. Del Papa (1), T. Zei (1),
L. Ruggeri (1), Y. Reisner (2), A. Velardi (1), F. Aversa (1),
M.F. Martelli (1)
Author address:
(1)University of Perugia (Perugia, IT); (2)Weizmann Institute of
Science (Rehovot, IL)
Full conference title:
Annual Meeting of the EBMT, 36th
Abstract:
Haploidentical transplantation, with extensive T cell depletion to
prevent GvHD, is associated with a high incidence of infectionrelated deaths. The key challenge is to improve immune recovery with allogeneic donor T cells without triggering GvHD. As T
regulatory cells (Tregs) controlled GvHD in preclinical studies, S75
the present phase I/II clinical trial evaluated the impact of early
infusion of donor CD4/CD25 + Tregs, followed by an inoculum
of donor mature T cells (Tcons) and positively immunoselected
CD34 + cells. Twenty-eight patients (median age 41, range 21-
60) were enrolled from September 2008 onwards; 22 had AML
(10 in CR1 at high risk, 10 in ≥ CR2 and 2 in relapse), 5 had ALL
(4 in CR1; 1 in relapse) and 1 had high grade NHL in relapse.
Conditioning was: 8Gy single fraction TBI, thiotepa (4 mg/kg x 2),
fl udarabine (40 mg/m² x 5), cyclophosphamide (35 mg/kg x 2).
All patients received immunoselected Tregs (CliniMACS,
Miltenyi Biotec) (23/28 2 x 10
6
/kg bw; 5/28 4 x 10
6
/kg bw) and
3 days later positively immunoselected CD34 + cells (median
8.2 x 10
6
/kg bw, range 5.0-19.1) together with Tcons (4/28
0.5 x 10
6
/kg bw; 17/28 1 x 10
6
/kg bw; 5/28 2 x 10
6
/kg bw; 2/28 did
not receive Tcons). CD4/CD25 + Tregs (purity 92.7±2.1) consisted of 33.6%±13.1 CD25
high
; 58.1%±6.6 CD25
int
; 5.8%±2.5
CD25
low
; 65.7%±11.8 FoxP3; 17.4%±7.2 CD127 (mean±SD). No
GvHD prophylaxis was administered. 26/28 patients engrafted.
No GvHD developed in 24/26 patients, 2 developed ≥ grade II
GvHD. Ten patients died (3 VOD, 2 fungal pneumonia, 1 bacterial sepsis, 1 CNS aspergillosis, 1 systemic toxoplasmosis,
1 adenoviral infection, 1 MOF). CD4 and CD8 counts reached,
respectively, 50/μL medianly on days 34 (range 19-63 days) and
24 (range 15-87); 100/μL medianly on days 47 (range 28-100
days) and 34 (range 19-95); 200/μL on days 70 (range 41-146
days) and 61 (range 21-95). A wide T-cell repertoire developed
rapidly with high frequencies of specifi c CD4 + and CD8 + for
opportunistic pathogens. Episodes of CMV reactivation were
signifi cantly fewer than after our “œstandard haplo” transplants.
In KIR ligand-mismatched transplants, speed of NK cell reconstitution/maturation and size of donor vs. recipient alloreactive
NK cell repertoires were preserved. In conclusion, in the setting of haploidentical transplantation infusion of Tregs makes
administration of a high dose of T cells feasible for the fi rst time.
This strategy provides a long-term protection from GvHD and
robust immune reconstitution.
Abstract Number: O383
Conference Year: 2010
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a